WO2004094402A1 - 新規なα‐グルコシダーゼ阻害活性を有する物質およびこれを含有する食品 - Google Patents
新規なα‐グルコシダーゼ阻害活性を有する物質およびこれを含有する食品 Download PDFInfo
- Publication number
- WO2004094402A1 WO2004094402A1 PCT/JP2004/005865 JP2004005865W WO2004094402A1 WO 2004094402 A1 WO2004094402 A1 WO 2004094402A1 JP 2004005865 W JP2004005865 W JP 2004005865W WO 2004094402 A1 WO2004094402 A1 WO 2004094402A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- glucosidase
- inhibitory activity
- salachia
- activity
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 42
- 239000000126 substance Substances 0.000 title claims abstract description 34
- 235000013305 food Nutrition 0.000 title claims abstract description 14
- 102100024295 Maltase-glucoamylase Human genes 0.000 title abstract description 6
- 108010028144 alpha-Glucosidases Proteins 0.000 title abstract description 6
- 230000000694 effects Effects 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 23
- 102000004366 Glucosidases Human genes 0.000 claims description 14
- 108010056771 Glucosidases Proteins 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 241000545263 Salacia <hydroid> Species 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 19
- 208000008589 Obesity Diseases 0.000 abstract description 9
- 235000020824 obesity Nutrition 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 5
- 230000000291 postprandial effect Effects 0.000 abstract description 3
- 229930014626 natural product Natural products 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
- 239000008103 glucose Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- SOWRVDSZMRPKRG-YRPOCYRVSA-N S(=O)(=O)(O[C@@H](CO)[C@@H](C[S@+]1[C@@H]([C@H]([C@@H](C1)O)O)CO)O)[O-] Chemical compound S(=O)(=O)(O[C@@H](CO)[C@@H](C[S@+]1[C@@H]([C@H]([C@@H](C1)O)O)CO)O)[O-] SOWRVDSZMRPKRG-YRPOCYRVSA-N 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 244000087020 Salacia prinoides Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 239000011976 maleic acid Substances 0.000 description 4
- -1 methanol Chemical class 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 3
- 102400000472 Sucrase Human genes 0.000 description 3
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000011073 invertase Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 244000039545 Salacia macrophylla Species 0.000 description 2
- 241000647991 Salacia reticulata Species 0.000 description 2
- 241000558327 Salacia undulata Species 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000222666 Boerhavia diffusa Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000233839 Commelina communis Species 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000134253 Lanka Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 244000293610 Morus bombycis Species 0.000 description 1
- 235000006721 Morus bombycis Nutrition 0.000 description 1
- 241000218998 Salicaceae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000014459 Sorbus Nutrition 0.000 description 1
- 241001092391 Sorbus Species 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- OMKXVFDVAGCPBS-GTEYUELZSA-N [(2s,3s,4r,5r,6s)-1-[(2r,3s,4s)-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium-1-yl]-2,4,5,6,7-pentahydroxyheptan-3-yl] sulfate Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](OS([O-])(=O)=O)[C@H](O)C[S+]1C[C@@H](O)[C@H](O)[C@H]1CO OMKXVFDVAGCPBS-GTEYUELZSA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 235000021098 high calorie intake Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a novel substance which is a substance having an a-glucosidase inhibitory activity effective for the prevention or treatment of diabetes and obesity, and which is particularly contained in a solvent extract from a plant belonging to the genus Salachia of the family Detinulaceae or the family Lyophaceae. It relates to a substance having glucosidase inhibitory activity.
- ⁇ -darcosidase is one of the digestive enzymes possessed by humans.
- This enzyme plays an important role in the biochemical process of biopolymers, breaking down disaccharides such as sucrose and maltose into monosaccharides (eg, glucose) that are easily absorbed by the body.
- disaccharides such as sucrose and maltose
- monosaccharides eg, glucose
- dalcosidase By inhibiting or modulating the function of dalcosidase, reducing the amount of sugar absorbed in the body, and thereby suppressing excessive postprandial rise in blood glucose, is the prevention and treatment of type II diabetes, and This is considered to be an effective means for obesity elimination and diabetes prevention in the reserve diabetes army.
- glucosidase inhibitors that have been developed to inhibit the function of glucosidase: Basin (Takeda Pharmaceutical Co., Ltd.) and Glucobay (Fiber trademark) (Bayer Yakuhin Kogyo Co., Ltd.) These drugs account for about 15% of the market for diabetes treatments.
- Basin Takeda Pharmaceutical Co., Ltd.
- Glucobay Fiber trademark
- Glucosidase inhibitors not only act as diabetes treatments, but also eliminate obesity due to overeating and lack of exercise.
- these human glucosidase inhibitors may rarely cause serious side effects such as hepatic dysfunction and hypoglycemia. They must be strictly prescribed under the supervision of a physician and are not readily available and ingestible.
- Substances having natural glucosidase inhibitory activity have attracted attention because they are safer for the living body than the synthetic drugs and have relatively less side effects.
- examples of such substances include mulberry (Morus bombycis Koidzumi) and communis
- Salachia reticulata is a vine perennial plant that grows naturally in southern India and northern Sri Lanka. Its roots and stems have been included in the traditional Asian medicine of Urveda, which has been used to relieve subjective symptoms (mouth disease) in anti-obesity and diabetes since ancient times.
- Salacinol and kolan lanol are also considered to be relatively safe for living organisms.
- the salacinol and lananol are each a thiosugar sulfonyl intramolecular sulfate structure represented by the following formula: It is.
- An object of the present invention is to provide a novel a-glucosidase which is highly safe for the human body, has a low risk of side effects, and has an effective inhibitory activity on glucosidase, and is effective for preventing diabetes and obesity.
- the aim was to find substances with inhibitory activity from natural products with less side effects than synthetic drugs. Disclosure of the invention
- the present inventors have further investigated in detail the inhibitory activity of hidalchosidase on a solvent extract from a plant belonging to the genus Dechinmulidae or Salixia spp.
- the above-mentioned Salachia reticulata belongs, especially a solvent extract from its roots and stems.
- the glucosidase activity was lower than that of these. I guessed that it contained high-performance substances. Therefore, as a result of further research, they have found a novel substance having an inhibitory activity on glucosidase.
- the present invention provides a substance having an a-glucosidase inhibitory activity represented by the following formula, which is contained in a solvent extract from the roots and stems of a plant belonging to the genus Salicia or Desinaceae. .
- reticulanol j in order to distinguish a substance having a novel glucose glucosidase inhibitory activity represented by the above formula from a known substance having a similar structure contained in a plant belonging to the genus Salachia (such as salacinol phenol).
- reticulanol j in order to distinguish a substance having a novel glucose glucosidase inhibitory activity represented by the above formula from a known substance having a similar structure contained in a plant belonging to the genus Salachia (such as salacinol phenol).
- reticulanol j in order to distinguish a substance having a novel glucose glucosidase inhibitory activity represented by the above formula from a known substance having a similar structure contained in a plant belonging to the genus Salachia (such as salacinol phenol).
- the substance "retikiuranol” having the inhibitory activity of hi-glucosidase of the present invention is contained in a solvent extract from the roots and stems of a plant belonging to the genus Salachia of the family Detinulaceae or the family Sorbus regius.
- the plants of the genus Salachia include, in addition to the Salachia 'Letikiura overnight, Salachia oblonga, Salacia chinensis (Salacia chinensis), Salachia' Salacia macrophylla (Salacia macrophylla) ⁇
- the retikiuranol of the present invention is contained in the solvent extract of the plant belonging to the genus Salachia.
- the outline of a method for preparing the solvent extract and a method for isolating and purifying reticulanol therefrom will be described below, and details thereof will be described in the following Examples.
- the extraction solvent may be selected from water or alcohols such as methanol, or a mixed solvent of water and an alcohol or a ketone such as acetone. Particularly preferably, water is used as the extraction solvent.
- the solvent extract is further subjected to liquid-liquid distribution with an organic solvent such as hexane, ethyl acetate, n-butanol for the purpose of removing unnecessary components and purifying the solvent extract. May be.
- an organic solvent such as hexane, ethyl acetate, n-butanol
- the substance ⁇ -glucosidase inhibitory activity of the present invention reticiuranol
- the desired retikiuranols of the present invention are particularly abundant in the water extracts from the roots and stems of Salachia's reticulata. include.
- reticulanol may be used alone or in the form of the above-mentioned solvent extract containing reticulanol before separation (for example, a composition containing reticulanol-a glucosidase-inhibiting active composition).
- the present invention further provides a food containing the reticulanol or the hyperglucosidase-inhibiting active composition of the present invention as an active ingredient.
- Such foods are effective, for example, not only in preventing and treating diabetes, but also in preventing and eliminating obesity.
- the food of the present invention is more preferably provided as an orally ingestible food. Therefore, the food of the present invention appropriately contains, in addition to the above-mentioned active ingredients, other known compounds commonly used in the pharmaceutical field, or compounds necessary for molding into powders, solid preparations or liquid preparations, and the like. May be. Examples of such compounds include erythritol, maltitol, hydroxypropyl cellulose, kaolin, talc, calcium carbonate and the like.
- the food of the present invention contains the reticle of the present invention in an amount capable of effectively functioning its glucosidase inhibitory activity, for example, at least 0.005 parts of reticle of the total weight of the food. 0.1% by weight, preferably 0.0005 to 0.01% %, More preferably from 0.01 to 0.005% by weight.
- the present invention will be described in more detail with reference to the following Preparation Examples and Examples, but the present invention is not limited to these Preparation Examples and Examples.
- Fr. 3-5 was found to be a new substance having the following structural formula, reticulanol (yield 0.0142%), based on the following various spectral data.
- test substances the reticulanol of the present invention obtained in Preparation Example 2 described above, and salacinol and konolanol for comparison were used.
- a test tube add 50 ⁇ L of a test sample (test substance concentration: 3 to 30 ⁇ g / mL) in which the test substance is dissolved in 0.1 M maleic acid buffer (pH 6.0), and add 74 mM sucrose aqueous solution 100 L each was dispensed and preliminarily heated at 37 ° C for 3 minutes in a water bath.
- the crude enzyme diluent was added thereto in 50 L portions, and reacted at 37 ° C. for 30 minutes.
- 800 L of purified water was added to each, and the mixture was further heated at 80 ° C for 3 minutes to inactivate the enzyme and stop the reaction.
- the glucose concentration in the reaction solution was quantified using the above-mentioned commercially available glucose CII Test Co. (Wako Pure Chemical Industries, Ltd.).
- reaction and quantification were performed in the same manner as described above, using salacinol obtained in Preparation Example 2 as a test substance for comparison.
- Sucrase inhibitory activity (%) ⁇ (Glc 0 -Glc x ) / Glc 0 ⁇ l00
- Glc x is the value of glucose in the corresponding blank test from the glucose concentration in the test sample.
- Gluc fl is the glucose concentration of the corresponding control, minus the glucose concentration.
- the inhibitory activity (%) calculated from the above equation was plotted on the vertical axis, and the concentration of each test substance (g / mL) was plotted on the horizontal axis to prepare an inhibition curve. From this inhibition curve, 50% inhibition concentration
- the resulting chewable tablets contain the Salachia 'retikiura overnight extract of the present invention, which exhibits a high glucose-inhibiting effect.
- Example 2 Production of a drink (the present invention)
- This drink formulation contains 100 mg of an aqueous solvent extract from Salachia reticuliura of the present invention per bottle as a component effective for the inhibitory effect of Hi-Darcosidase.
- the novel substance a-darcosidase inhibitory activity of the present invention is contained in a solvent extract of a natural plant, and is a thiosaccharide similar to known active ingredients (salacinol and kosunolanol). It has a sulfonyl intramolecular sulfate structure.
- the retikiuranol of the present invention is derived from a natural plant that has been used in traditional medicine in South Asia for many years, and therefore has higher safety for living organisms than synthetic drugs.
- the retikiuranol of the present invention can be taken daily, for example, by blending it into foods and the like.
- Such foods are effective not only in the prevention of diabetes but also in alleviating the symptoms of diabetic patients (ie, treatment) due to their ability to suppress postprandial hyperglycemia due to the inhibitory activity of retikiuranol on dalcosidase. ) Can also be expected.
- the retikiuranol of the present invention has excellent a-glucosidase inhibitory activity. Therefore, it is thought that there is a high possibility that it will be a lead drug in future drugs. This has made Retikiuranol one of the compounds that have been shown to potentially improve blood sugar levels in Salachia plants.
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04729237A EP1645557A1 (en) | 2003-04-24 | 2004-04-23 | Novel substance having alpha-glucosidase inhibiting activity and food containing the same |
US10/553,943 US20070037870A1 (en) | 2003-04-24 | 2004-04-23 | Novel substance having alpha-glucosidase inhibiting activity and food containing the same |
CA002522793A CA2522793A1 (en) | 2003-04-24 | 2004-04-23 | Novel substance having .alpha.-glucosidase inhibiting activity and food containing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-120317 | 2003-04-24 | ||
JP2003120317A JP4516282B2 (ja) | 2003-04-24 | 2003-04-24 | 新規なα−グルコシダーゼ阻害活性を有する物質およびこれを含有する食品 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004094402A1 true WO2004094402A1 (ja) | 2004-11-04 |
Family
ID=33308130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/005865 WO2004094402A1 (ja) | 2003-04-24 | 2004-04-23 | 新規なα‐グルコシダーゼ阻害活性を有する物質およびこれを含有する食品 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070037870A1 (ja) |
EP (1) | EP1645557A1 (ja) |
JP (1) | JP4516282B2 (ja) |
CA (1) | CA2522793A1 (ja) |
WO (1) | WO2004094402A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008065796A1 (fr) * | 2006-11-30 | 2008-06-05 | Fuji-Sangyo Co., Ltd. | Inhibiteur de l'α -glucosidase |
EP1999124A1 (en) * | 2006-03-02 | 2008-12-10 | Simon Fraser University | Glycosidase inhibitors and methods of synthesizing same |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1653945A2 (en) * | 2003-06-25 | 2006-05-10 | Simon Fraser University | Glycosidase inhibitors and methods of synthesizing same |
PT103385B (pt) * | 2005-11-15 | 2011-06-27 | Jorge Ruas Da Silva | Ácido 2,3,4,5-tetrahidróxi-6-sulfooxi-hexanoico, seus sais farmaceuticamente aceitáveis e suas formas de equilíbrio, processo para a sua preparação, composições farmacêuticas contendo estes compostos e seu uso em medicina |
US20080241292A1 (en) * | 2006-10-27 | 2008-10-02 | Iomedix Development International Srl | Composition and method for weight loss |
WO2008099423A2 (en) * | 2007-02-15 | 2008-08-21 | Swaminathan. S. | A novel herbal drug and a process for preparation thereof for the prevention and management of endothellal dysfunction among type-ii diabetes mellitus cases |
JP2009060792A (ja) | 2007-09-04 | 2009-03-26 | Fujifilm Corp | 錠剤またはカプセル剤の食品。 |
JP5638180B2 (ja) | 2007-09-06 | 2014-12-10 | 富士フイルム株式会社 | サラシア属植物の抽出物とフラボノイドを含有する食品 |
JP5212687B2 (ja) * | 2007-10-11 | 2013-06-19 | 学校法人近畿大学 | α−グルコシダーゼ阻害活性を有する化合物の定量方法、及びサラキア属植物又はその抽出液のα−グルコシダーゼ阻害活性評価法 |
JP2009249315A (ja) * | 2008-04-03 | 2009-10-29 | Fujifilm Corp | ミネラル吸収促進剤ならびに鉄欠乏性貧血改善剤または食品組成物 |
JP2011015670A (ja) * | 2009-07-08 | 2011-01-27 | Ichiban Lifetech Solutions株式会社 | アーユルヴェーダ伝統製品の飲料化 |
JP5934120B2 (ja) | 2011-01-31 | 2016-06-15 | 学校法人近畿大学 | 環状スルホニウム塩、その製造方法およびそれを用いたα−グルコシダーゼ阻害剤 |
US9849151B2 (en) | 2013-11-19 | 2017-12-26 | OmniActive Health Technologies (Canada) Limited | Salacia compositions, methods of treatment by their administration, and methods of their preparation |
JP2014051535A (ja) * | 2013-12-19 | 2014-03-20 | Fujifilm Corp | 鉄、カルシウム、又はマグネシウムの吸収を促進する方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1129472A (ja) * | 1997-07-07 | 1999-02-02 | Res Inst For Prod Dev | α−グルコシダーゼの阻害作用を有する化合物 |
JP2000086653A (ja) * | 1998-09-14 | 2000-03-28 | Ranka Aayurubeedick Haabu Yakuhin Kk | 二糖加水分解酵素阻害剤 |
JP2001103928A (ja) * | 1999-10-08 | 2001-04-17 | Fancl Corp | 食品組成物 |
WO2001049674A2 (en) * | 2000-01-07 | 2001-07-12 | Simon Fraser University | Glycosidase inhibitors and preparation thereof |
JP2002104979A (ja) * | 2000-09-29 | 2002-04-10 | Nippon Kefia Kk | ケフィアを用いた糖尿病治療剤とその製造方法、及びケフィアを用いた放射線障害防護剤、並びにケフィアを用いた健康食品 |
JP2003171299A (ja) * | 2001-11-30 | 2003-06-17 | Bio Venture Bank Kk | 単糖類を含有してなる新規コタラヒム抽出物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376682B1 (en) * | 2000-02-01 | 2002-04-23 | Takama System, Ltd. | Compound with α-glucosidase inhibiting action and method for producing the same |
JP2003245057A (ja) * | 2002-02-25 | 2003-09-02 | Sakamoto Yakusoen:Kk | 嗜好品用添加剤 |
-
2003
- 2003-04-24 JP JP2003120317A patent/JP4516282B2/ja not_active Expired - Lifetime
-
2004
- 2004-04-23 WO PCT/JP2004/005865 patent/WO2004094402A1/ja active Application Filing
- 2004-04-23 EP EP04729237A patent/EP1645557A1/en not_active Withdrawn
- 2004-04-23 US US10/553,943 patent/US20070037870A1/en not_active Abandoned
- 2004-04-23 CA CA002522793A patent/CA2522793A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1129472A (ja) * | 1997-07-07 | 1999-02-02 | Res Inst For Prod Dev | α−グルコシダーゼの阻害作用を有する化合物 |
JP2000086653A (ja) * | 1998-09-14 | 2000-03-28 | Ranka Aayurubeedick Haabu Yakuhin Kk | 二糖加水分解酵素阻害剤 |
JP2001103928A (ja) * | 1999-10-08 | 2001-04-17 | Fancl Corp | 食品組成物 |
WO2001049674A2 (en) * | 2000-01-07 | 2001-07-12 | Simon Fraser University | Glycosidase inhibitors and preparation thereof |
JP2002104979A (ja) * | 2000-09-29 | 2002-04-10 | Nippon Kefia Kk | ケフィアを用いた糖尿病治療剤とその製造方法、及びケフィアを用いた放射線障害防護剤、並びにケフィアを用いた健康食品 |
JP2003171299A (ja) * | 2001-11-30 | 2003-06-17 | Bio Venture Bank Kk | 単糖類を含有してなる新規コタラヒム抽出物 |
Non-Patent Citations (6)
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8389565B2 (en) | 2000-01-07 | 2013-03-05 | Simon Fraser University | Glycosidase inhibitors and methods of synthesizing same |
EP1999124A1 (en) * | 2006-03-02 | 2008-12-10 | Simon Fraser University | Glycosidase inhibitors and methods of synthesizing same |
EP1999124A4 (en) * | 2006-03-02 | 2010-10-06 | Univ Fraser Simon | GLYCOSIDASE INHIBITORS AND METHODS OF SYNTHESIZING THE SAME |
WO2008065796A1 (fr) * | 2006-11-30 | 2008-06-05 | Fuji-Sangyo Co., Ltd. | Inhibiteur de l'α -glucosidase |
Also Published As
Publication number | Publication date |
---|---|
JP4516282B2 (ja) | 2010-08-04 |
EP1645557A1 (en) | 2006-04-12 |
US20070037870A1 (en) | 2007-02-15 |
JP2004323420A (ja) | 2004-11-18 |
CA2522793A1 (en) | 2004-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4669920B2 (ja) | 血糖上昇抑制且つ血圧上昇抑制作用を有する機能性素材 | |
JP5937596B2 (ja) | 活性型フラボノイド化合物の含量が増加されたウルシ抽出物及びその製造方法 | |
WO2004094402A1 (ja) | 新規なα‐グルコシダーゼ阻害活性を有する物質およびこれを含有する食品 | |
EP2438923B1 (en) | Composition for preventing or treating obesity-related diseases mediated by the activation of ampk and including 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignans as active ingredients | |
US20120315332A1 (en) | Pharmaceutical composition including sunflower extract, preparative method and use thereof | |
EP2251024A1 (en) | Plant-origin drug for preventing or improving hyperuricemia | |
JPH09176019A (ja) | 糖質分解消化酵素阻害剤並びにこれを配合した医薬品および飲食品 | |
US6376682B1 (en) | Compound with α-glucosidase inhibiting action and method for producing the same | |
JP6601860B2 (ja) | グルコース吸収抑制剤 | |
CN100586429C (zh) | 一种抗抑郁药物 | |
JP2009523135A (ja) | 文冠果抽出物並びに抽出及び使用 | |
WO2009151173A1 (en) | Pharmaceutical compositions for prevention and treatment of viral diseases containing rhodiola extracts, fractions, the isolated flavonoid compounds therefrom, derivatives compounds thereof or the pharmaceutically acceptable salts as an active ingredient | |
JP2009057319A (ja) | α−グルコシダーゼ阻害剤、エリオジクチオール−7−O−グルコシド含有物の製造方法、及びこれを含有する飲食品 | |
KR101119410B1 (ko) | 회향근 추출물을 유효성분으로 포함하는 염증성 질환 치료 및 예방용 조성물 | |
KR20140137640A (ko) | 참나무 분획 복합 추출물 및 이를 유효성분으로 함유하는 당뇨병 치료 또는 예방용 조성물 | |
JP2008007473A (ja) | 決明子抽出物 | |
KR20140047247A (ko) | 페오포바이드 a와 같은 포피린계 물질을 유효성분으로 함유하는 항산화 제재와, 당뇨병 및 당뇨합병증 예방 또는 치료용 조성물 | |
KR101062003B1 (ko) | 사방오리나무 추출물 또는 그로부터 분리된 화합물을 유효성분으로 하는 당뇨병 예방 및 치료용 조성물 | |
JP5655416B2 (ja) | 新規フラバン化合物 | |
CN114292302B (zh) | 一种从黄皮叶子中提取的化合物及其制备工艺和应用 | |
JP2014155489A (ja) | サルトリイバラ葉抽出物を含有する糖尿予防及び治療用の組成物 | |
EP4356756A1 (en) | Composition for preventing, improving, or treating degenerative arthritis comprising steamed ginger extract or 1-dehydro-6-gingerdione isolated therefrom as active ingredient | |
CN108421020A (zh) | 一种用于治疗糖尿病视网膜病的生姜提取物及其制备方法和用途 | |
JP2002053475A (ja) | 糖質分解酵素阻害剤およびそれを含有する飲食品 | |
RU2780346C1 (ru) | Терапевтический агент против коронавируса, включающий экстракт elaeocarpus sylvestris |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2522793 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004729237 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007037870 Country of ref document: US Ref document number: 10553943 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004729237 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10553943 Country of ref document: US |